Subchronic phencyclidine in rats: Alterations in locomotor activity, maze performance, and GABAA receptor binding

Behavioural Pharmacology

Volumn 21, Issue 1, 2010, Pages 1-10

  Beninger, Richard J ^a,b   Beuk, Jonathan ^a   Banasikowski, Tomek J ^a   Van Adel, Michael ^b   Boivin, Gregory A ^b   Reynolds, James N ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Dopamine; Glutamate; Memory; Muscimol; N methyl D aspartate receptors; Rat; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID CARRIER; AMPHETAMINE; GLUTAMATE DECARBOXYLASE; MUSCIMOL; PHENCYCLIDINE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; BINDING AFFINITY; BINDING SITE; BRAIN; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HIPPOCAMPUS; LEARNING; LOCOMOTION; MALE; MAZE TEST; MEMORY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR BINDING; SPRAGUE DAWLEY RAT; TASK PERFORMANCE;

AMPHETAMINE; ANIMALS; CORPUS STRIATUM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FRONTAL LOBE; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMATE DECARBOXYLASE; HIPPOCAMPUS; MALE; MAZE LEARNING; MOTOR ACTIVITY; MUSCIMOL; PHENCYCLIDINE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 74549202693     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283347091     Document Type: Article

References (59)

1. Abdul-Monim Z, Reynolds GP, Neill JC (2006). The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169:263-273.
2. Abdul-Monim Z, Neill JC, Reynolds GP (2007). Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbu-min-immunoreactive expression in the rat. J Psychopharmacol 21:198-205.
3. 3H] flunitrazepam binding in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 29:133-140.
4. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97:8104-8109.
5. Audet MC, Goulet S, Dore FY (2007). Enhanced anxiety follows withdrawal from exposure to phencyclidine in rats. Behav Brain Res 176:358-361.
6. A receptor subunit protein expression in the adult guinea pig cerebral cortex. J Neurosci 21:4381-4389.
7. Benes FM, Berretta S (2001). GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmaco-logy 25:1-27.
8. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991). Deficits in small interneurons in prefrontal and cingulated cortexes of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001.
9. Benes FM, Khan Y, Vincent SL, Wickramasinghe R (1996). Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 22:338-349.
10. Beninger RJ, Cooper TA, Mazurski EJ (1985). Automating the measurement of locomotor activity. Neurobehav Toxicol Teratol 7:79-86.
11. Beninger RJ, Wasserman J, Zanibbi K, Charbonneau D, Mangels J, Beninger BV (2003). Typical and atypical antipsychotic medications differentially affect two non-declarative memory tasks in schizophrenic patients: a double dissociation. Schizophr Res 61:281-292.
12. Beninger RJ, Forsyth JK, Van Adel M, Reynolds JN, Boegman R J, Jhamandas K (2009). Subchronic MK-801 behavioural deficits in rats: partial reversal by the novel nitrate GT 1061. Pharmacol Biochem Behav 91:495-502.
13. Biggan SL, Beninger RJ, Cockhill J, Jhamandas K, Boegman RJ (1991). Quisqualate lesions of rat NBM: selective effects on working memory in a double Y-maze. Brain Res Bull 26:613-616.
14. Bradford M (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
15. Carlsson A (1998). The current status of the dopamine hypothesis of schizophrenia. Neurophychopharmacology 1:179-186.
16. Carlsson A,Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260.
17. Costa E, Davis JM, Dong E, Greyson DR, Guidotti A, Tremolizoo L, Veldic M (2004). A GABAergic cortical deficit dominated schizophrenia patho-physiology. Crit Rev Neurobiol 16:1-23.
18. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C, Opeskin K, Copolov DL (1999). Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 72: 1593-1599.
19. Du Bois TM, Deng C, Han M, Newell KA, Huang X (2009). Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. Eur Neuropsychopharmacol 4:256-265.
20. Dunn MJ, Killcross S (2006). Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance. Behav Brain Res 175:271-277.
21. Ebert B, Thompson SA, Saounatsou K, McKernan R, Krogssgard-Larsen P, Wafford KA (1997). Differences in agonist/antagonist binding affinity and receptor transduction using recombinant human g-aminobutyric acid type a receptors. Mol Pharmacol 52:1150-1156.
22. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007). New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
23. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Prog Neuropsychopharmacol Biol Psychiatry 32:336-339. (Pubitemid 351178944)
24. Gao XM, Shirakawa O, Du F, Tamminga CA (1993). Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol 241:7-15.
25. Goldberg TE, Weinberger DR (1988). Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull 14:179-183.
26. Greene R (2001). Circuit analysis of NMDA hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11:569-577.
27. Guidotti A, Auta J, Davis JM, Gerevini VD, Dwivedi Y, Grayson RD, et al. (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57:1061-1069.
28. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18:448-454.
29. 3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40:259-266.
30. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M (2008a). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 18:414-421. (Pubitemid 351608551)
31. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, Tsukada H, Iyo M (2008b). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63:92-97. (Pubitemid 350234890)
32. Hendrickson AE, Tillakaratne NJ, Mehra RD, Esclapez M, Erickson A, Vician L, Tobin AJ (1994). Differential localization of two glutamic acid decarboxylases (GAD65 and GAD67) in adult monkey visual cortex. J Comp Neurol 343:566-581.
33. Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69-108.
34. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
35. Jentsch JD, Taylor JR (2000). Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuro-psychopharmacology 24:66-74.
36. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997a). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 227:953-955.
37. Jentsch JD, Tran A, Le D, Youngren KD, Phill M, Roth RH (1997b). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsycho-pharmacology 17:92-99.
38. Jentsch JD, Taylor JR, Roth RH (1998). Subchronic phencyclidine administration increases mesolimbic dopamine system responsivity and augments stress-and amphetamine-induced hyperlocomotion. Neuropsychopharmacology 19:105-113.
39. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520.
40. Lewis DA, Volk DW, Hashimoto T (2004). Selective alterations in the prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174:143-150.
41. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962). Model psychoses and schizophrenia. Am J Psychiatry 119:61-67.
42. Mallet PE, Beninger RJ (1993). The double Y-maze as a tool for assessing memory in rats. Neurosci Protocols 02:1-11.
43. McLean SL, Beck JP, Woolley ML, Neill JC (2008). A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 189:152-158.
44. McLean SL, Idris NF, Woolley ML, Neill JC (2009a). D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuro-psychopharmacol 19:440-450.
45. McLean SL, Woolley ML, Thomas D, Neill JC (2009b). Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl) 226:403-414.
46. Morris BJ, Cochran SM, Pratt JA (2005). PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 5:101-106.
47. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
48. Olney JW, Labruyere J, Want G, Wozniak DF, Prince MT, Sesma MA (1991). NMDA antagonist neurotoxicity: mechanisms of prevention. Science 254:1515-1518.
49. Pratt JA, Winchester C, Egerton A, Cochran SM, Morris BJ (2008). Modelling prefrontal cortex deficits in schizophrenia: Implications for treatment. Br J Pharmacol 153 (Suppl 1):S465-S470.
50. Reynolds GP, Abdul-Monim Z, Neill JC, Zhang ZJ (2004). Calcium binding protein markers of GABA defecits in schizophrenia-post mortem studies and animal models. Neurotox Res 6:57-62.
51. Riley B, Kendler KS (2006). Molecular genetic studies of schizophrenia. Eur J Hum Genet 14:669-680.
52. Rodefer JS, Murphy ER, Baxter MG (2005). PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070-1076.
53. Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008). Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychophar- macology 33:2657-2666.
54. Schroeder U, Schroeder H, Schwegler H, Sabel BA (2000). Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. Br J Pharmacol 130:33-40.
55. Snyder SH (1972). Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry 27:169-179.
56. Stefani MR, Moghaddam B (2002). Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 134:267-274.
57. Wang C, Yang SF, Xia Y, Johnson KM (2008). Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. Neuropsychopharmacology 33:2442-2456.
58. Weinberger DR, Lipska BK (1995). Cortical maldevelopment, anti-psychotic drugs and schizophrenia: a search for common ground. Schizophr Res 16:87-110.
59. Xi D, Zhang W, Wang HX, Stradtman GG, Gao WJ (2009). Dizocilpine (MK-801) induces distinct changes of N-methyl-d-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex. Int J Neuropsychopharmacol 13:1-14.